3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Colorectal Neoplasms
18
Carcinoma, Non-Small-Cell Lung
14
Breast Neoplasms
14
Lung Neoplasms
12
Head and Neck Neoplasms
10
Rectal Neoplasms
8
Prostatic Neoplasms
7
Mouth Neoplasms
5
Glioblastoma
5
Esophageal Neoplasms
5
Colonic Neoplasms
5
Central Nervous System Neoplasms
5
Pancreatic Neoplasms
4
Oropharyngeal Neoplasms
4
Neoplasm Metastasis
4
Hypopharyngeal Neoplasms
4
Gliosarcoma
4
Carcinoma
4
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma
3
Ovarian Neoplasms
3
Neuroblastoma
3
Neoplasms
3
Laryngeal Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Dysplasia
2
Turcot syndrome
2
Tongue Neoplasms
2
Salivary Gland Neoplasms
2
Recurrence
2
Interventions
Cisplatin
8
Etoposide
6
Paclitaxel
5
Ifosfamide
4
Sunitinib
3
Oxaliplatin
3
Cyclophosphamide
3
Brentuximab Vedotin
3
tremelimumab
2
pembrolizumab
2
etoposide phosphate
2
durvalumab
2
Sirolimus
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Dexamethasone
2
Carboplatin
2
Bleomycin
2
Bevacizumab
2
tozuleristide
1
rolapitant
1
ribociclib
1
pegfilgrastim
1
pazopanib
1
olaparib
1
fosaprepitant
1
fludarabine phosphate
1
fludarabine
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Germ Cell and Embryonal
×
Celecoxib
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled